The latest investment round in Q2 2019 brought in 20mio SEK, with the main investors being Lars Stigsson (Kiram AB) and Almi Invest Syd AB, which enabled Amniotics™ to build a GMP propagation facility and conduct preclinical studies. Amniotics™ being on the doorstep for initiating clinical trials, is anew looking for investors to help us bring lifechanging therapies to patients

Potential investors or collaborators are encouraged to contact management for further discussions.    

Articles of Association

Registration certificate from Bolagsverket

Annual Report 2019

Annual Report 2020

Q1 report 2021

WP to LinkedIn Auto Publish Powered By :